Senhwa Biosciences (ROCO:6492) Cyclically Adjusted Book per Share: NT$18.79 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6492 Senhwa Biosciences Inc ROCO:6492
70 GF Score
Price NT$43.50
GF Value NT$46.74
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Senhwa Biosciences Cyclically Adjusted Book per Share?

Senhwa Biosciences ROCO:6492 -1.35% 70 Cyclically Adjusted Book per Share is NT$18.79 as of Dec. 2025. GuruFocus rates ROCO:6492 with a GF Score™ of 70/100 and a GF Value™ of NT$46.74 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Senhwa Biosciences's adjusted book value per share for the three months ended in Dec. 2025 was NT$8.513. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$18.79 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Senhwa Biosciences's average Cyclically Adjusted Book Growth Rate was -1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-15), Senhwa Biosciences's current stock price is NT$43.50. Senhwa Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$18.79. Senhwa Biosciences's Cyclically Adjusted PB Ratio of today is 2.32.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Senhwa Biosciences was 3.17. The lowest was 1.69. And the median was 2.32.


Senhwa Biosciences  (ROCO:6492) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Senhwa Biosciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=43.50/18.79
=2.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Senhwa Biosciences was 3.17. The lowest was 1.69. And the median was 2.32.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Senhwa Biosciences Cyclically Adjusted Book per Share Related Terms


Senhwa Biosciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Senhwa Biosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senhwa Biosciences Cyclically Adjusted Book per Share Chart

Senhwa Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 19.06 18.79

Senhwa Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.06 19.12 19.12 19.00 18.79

ROCO:6492 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Senhwa Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senhwa Biosciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senhwa Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Senhwa Biosciences's Cyclically Adjusted PB Ratio falls into.


ROCO:6492
70GF Score
Senhwa Biosciences Inc ROCO:6492
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senhwa Biosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Senhwa Biosciences's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=8.513/324.0540*324.0540
=8.513

Current CPI (Dec. 2025) = 324.0540.

Senhwa Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201603 0.000 238.132 0.000
201606 9.257 241.018 12.446
201609 8.438 241.428 11.326
201612 7.611 241.432 10.216
201703 6.355 243.801 8.447
201706 23.482 244.955 31.065
201709 22.083 246.819 28.993
201712 20.626 246.524 27.113
201803 19.821 249.554 25.738
201806 18.188 251.989 23.389
201809 17.107 252.439 21.960
201812 15.889 251.233 20.494
201903 14.124 254.202 18.005
201906 12.929 256.143 16.357
201909 11.908 256.759 15.029
201912 10.884 256.974 13.725
202003 9.794 258.115 12.296
202006 8.951 257.797 11.252
202009 26.871 260.280 33.455
202012 25.957 260.474 32.293
202103 24.951 264.877 30.525
202106 24.233 271.696 28.903
202109 23.276 274.310 27.497
202112 22.048 278.802 25.627
202203 21.090 287.504 23.771
202206 20.032 296.311 21.908
202209 19.159 296.808 20.918
202212 18.097 296.797 19.759
202303 17.263 301.836 18.534
202306 16.556 305.109 17.584
202309 15.739 307.789 16.571
202312 14.769 306.746 15.602
202403 14.087 312.332 14.616
202406 13.315 314.175 13.734
202409 12.390 315.301 12.734
202412 11.516 315.605 11.824
202503 10.836 319.799 10.980
202506 10.126 322.561 10.173
202509 9.405 324.800 9.383
202512 8.513 324.054 8.513

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$18.79 mean?
Senhwa Biosciences (ROCO:6492) has a Cyclically Adjusted Book per Share of NT$18.79 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Senhwa Biosciences and its competitors.
Is Senhwa Biosciences' Cyclically Adjusted Book per Share too high?
Senhwa Biosciences' current Cyclically Adjusted Book per Share is NT$18.79. Overall, Senhwa Biosciences has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Senhwa Biosciences' Cyclically Adjusted Book per Share compare to VRTX and REGN?
Senhwa Biosciences' Cyclically Adjusted Book per Share of NT$18.79 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Senhwa Biosciences and its competitors. Senhwa Biosciences's current Cyclically Adjusted Book per Share is NT$18.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senhwa Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Senhwa Biosciences (ROCO:6492) is currently considered Fairly Valued. The stock's GF Value™ is NT$46.74, compared to a current price of NT$43.50 — trading 6.9% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$18.79. Senhwa Biosciences' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Senhwa Biosciences (ROCO:6492), the current Cyclically Adjusted Book per Share is NT$18.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Senhwa Biosciences (ROCO:6492) Overvalued in 2026?

Based on GuruFocus' analysis, Senhwa Biosciences stock appears to be undervalued. The current stock price of NT$43.50 is trading 6.9% below its estimated GF Value™ of NT$46.74. GuruFocus considers Senhwa Biosciences to be Fairly Valued.

Key valuation signals for ROCO:6492:

  • Cyclically Adjusted Book per Share: NT$18.79
  • GF Value™: NT$46.74 vs. price of NT$43.50 (6.9% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6492 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Senhwa Biosciences Business Description

Address Peihsin Road, 10th Floor, No. 225, Section 3, Hsintien District, New Taipei City, TWN, 23143
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients, focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), being developed as a therapy for solid tumours, B-cell lymphoma, ovarian cancer, and other oncology indications; and Silmitasertib (CX-4945), being developed to counter neuroblastoma, medulloblastoma, basal cell carcinoma, and other indications. Geographically, the company generates all of its revenue from Taiwan.
70GF Score

Get the complete analysis for ROCO:6492

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$43.50
Price
NT$46.74
GF Value